Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
NRX Pharmaceuticals (NRXP)
NASDAQ:NRXP
RESEARCH TOOLSreports
NRXP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.10 - $7.33
Previous CloseN/A
Volume2.07M
Average Volume (3M)965.76K
Market Cap
$42.71M
Enterprise Value$23.57M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Mar 27, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.15
Shares Outstanding15,700,369
10 Day Avg. Volume338,375
30 Day Avg. Volume965,762
Standard Deviation0.31
R-Squared0.07
Alpha-0.06
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.71K
Enterprise Value/Ebitda-1.23
Forecast
1Y Price Target
$32.00Price Target Upside1303.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
NRX Pharmaceuticals News
PremiumCompany Announcements
NRX Pharmaceuticals Board Changes and Nasdaq Compliance
PremiumCompany Announcements
NRX Pharmaceuticals Announces Board Resignation and New Nominee
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPositive clinical trials data in its Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression.
Market PotentialThere is no medicine approved to treat patients with bipolar depression suffering suicidal ideation, presenting a large market potential.
Bears Say
Financial PerformanceThe company reported a net loss of $7.9 million or EPS of $(0.75), missing consensus estimates.
---
Ownership Overview
9.66% Insiders
1.96% Mutual Funds
3.35% Other Institutional Investors
81.86% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NRXP FAQ
What was NRX Pharmaceuticals’s price range in the past 12 months?
NRX Pharmaceuticals lowest stock price was $1.10 and its highest was $7.33 in the past 12 months.
What is NRX Pharmaceuticals’s market cap?
NRX Pharmaceuticals’s market cap is $42.71M.
When is NRX Pharmaceuticals’s upcoming earnings report date?
NRX Pharmaceuticals’s upcoming earnings report date is Mar 27, 2025 which is in 33 days.
How were NRX Pharmaceuticals’s earnings last quarter?
NRX Pharmaceuticals released its earnings results on Nov 14, 2024. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.555 by $0.405.
Is NRX Pharmaceuticals overvalued?
According to Wall Street analysts NRX Pharmaceuticals’s price is currently Undervalued.
Does NRX Pharmaceuticals pay dividends?
NRX Pharmaceuticals does not currently pay dividends.
What is NRX Pharmaceuticals’s EPS estimate?
NRX Pharmaceuticals’s EPS estimate is -0.32.
How many shares outstanding does NRX Pharmaceuticals have?
NRX Pharmaceuticals has 15,700,369 shares outstanding.
What happened to NRX Pharmaceuticals’s price movement after its last earnings report?
NRX Pharmaceuticals reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.555. Following the earnings report the stock price went up 2.586%.
Which hedge fund is a major shareholder of NRX Pharmaceuticals?
Currently, no hedge funds are holding shares in NRXP
---
NRX Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.00 (1303.51% Upside)
$32.00 (1303.51% Upside)
Hedge Fund Trend
Increased
By 50.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $46.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-45.54%
12-Months-Change
Fundamentals
Return on Equity
108.28%
Trailing 12-Months
Asset Growth
-65.96%
Trailing 12-Months
Company Description
NRX Pharmaceuticals
Big Rock Partners Acquisition Corp. is a blank check company, which was formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, reorganization, recapitalization or other similar business combination with one or more businesses or entities. It focuses on identifying a prospective target business in the senior housing and care industry in the United States. The firm's care segments are commonly divided into four categories: Independent Living; Assisted Living; Memory Care and Nursing Care. The company was founded on September 18, 2017 and is headquartered in Delray Beach, FL.
---
NRXP Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in reducing operating losses, advancing drug development, and strategic acquisitions. However, challenges remain in cash reserves, acquisition strategies, and revenue recognition policies. The company's outlook is optimistic with planned new drug applications and potential profitability by 2025.Read More>---
NRXP Stock 12 Month Forecast
Average Price Target
$32.00
▲(1303.51% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Alaunos Therapeutics
―
Karyopharm Therapeutics
―
Evolus
―
Atea Pharmaceuticals
―
Best Analysts Covering NRXP
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
-14.98%
reiterated a buy rating 3 months ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -14.98% per trade.
---